:: infobox .infobox-protein
| KCNK2 Protein (TREK-1 Potassium Channel) | |
|---|---|
| Gene | KCNK2 |
| UniProt | O95069 |
| Molecular Weight | ~56 kDa (each subunit) |
| Subcellular Localization | Plasma membrane |
| Protein Family | Two-pore domain potassium (K2P) channel family |
| Aliases | TASK1, K2P2.1, TREK-1, TWIK-related potassium channel 1 |
| Structure | Homodimer, 4 transmembrane domains per subunit |
| Ion Selectivity | K+ selective |
| Channel Type | Leak/background potassium channel |
:::
TREK-1 (TWIK-related potassium channel 1), encoded by the KCNK2 gene, is a member of the two-pore domain potassium (K2P) channel family that regulates background leak currents and neuronal excitability[1]. These channels play critical roles in maintaining the resting membrane potential and responding to physiological and pathological stimuli. KCNK2 is widely expressed in the brain and has been implicated in various neurological conditions including epilepsy, migraine, depression, and neurodegenerative diseases[2].
KCNK2 (TREK-1) is a two-pore domain potassium channel with distinctive structural features:
The channel's structural arrangement creates a K+-selective pore that conducts leak currents at negative membrane potentials. This architecture distinguishes K2P channels from voltage-gated potassium (Kv) channels which have a single pore per subunit[4].
TREK-1 responds to multiple physiological stimuli through distinct activation mechanisms:
TREK-1 shows widespread CNS expression:
TREK-1 activation mediates neuroprotective responses during ischemic stroke. Mechanical stress from edema activates TREK-1 channels, producing hyperpolarization that reduces NMDA receptor-mediated excitotoxicity[6]. TREK-1 knockout mice show larger infarcts following middle cerebral artery occlusion.
Altered TREK-1 expression contributes to hyperexcitability in epilepsy. Seizure-induced mechanical and chemical changes affect TREK-1 function. Human epilepsy tissue shows reduced TREK-1 expression in seizure foci[7].
TREK-1 was the first ion channel directly linked to major depressive disorder. Antidepressant drugs including selective serotonin reuptake inhibitors (SSRIs) inhibit TREK-1. TREK-1 knockout mice exhibit antidepressant-like phenotypes[8].
TREK-1 in sensory neurons modulates mechanical and thermal pain thresholds. The channel contributes to mechano-sensitive pain pathways and represents a target for novel analgesics[9].
Emerging evidence suggests K2P channel dysfunction in Alzheimer's disease. Amyloid-beta peptides interact with neuronal membranes to alter TREK-1 gating, potentially contributing to excitability changes in AD[10].
Preliminary studies suggest TREK-1 expression changes in substantia nigra dopaminergic neurons in PD models. Further research is needed to clarify the role.
TREK-1 is modulated by multiple intracellular signaling mechanisms:
TREK-1 activators are being developed for stroke and traumatic brain injury treatment. Lead compounds have shown efficacy in preclinical models[6:1].
Understanding TREK-1 inhibition by existing antidepressants informs novel drug development. Selective TREK-1 modulators may offer alternatives to current treatments[8:1].
TREK-1 activators could provide analgesia through peripheral sensory neuron modulation without opioid liabilities[9:1].
Direct TREK-1 activators represent a novel approach to reduce excitotoxic damage following stroke.
Key experimental approaches:
TREK-1 interacts with:
Patel AJ, Lazdunski M, Honore E. Lipid and mechano-sensitivity of two-pore domain K+ channels. EMBO Rep. 2001. ↩︎
Honore E. The neuronal background K2P channels: from basic physiology to disease. Nat Rev Neurosci. 2007. ↩︎
Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol. 2000. ↩︎
Miller AN, Long SB. Crystal structure of the potassium channel KirBac1.1 in the closed state. Science. 2012. ↩︎
Maingret F, Patel AJ, Lesage F, et al. Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J Biol Chem. 1999. ↩︎
Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004. ↩︎ ↩︎
Pang DS, Robelet C, Guglielmetti C, et al. Altered expression of TASK-1 and TASK-3 in rat and human temporal lobe epilepsy. J Neurophysiol. 2009. ↩︎
Luckhart C, Liedtke WB, Ghose S. The role of TREK-1 in depression and antidepressant action. Neuropharmacology. 2021. ↩︎ ↩︎
Alloui A, Zimmermann K, Mamet J, et al. TREK-1, a K+ channel involved in polymodal pain perception. EMBO J. 2006. ↩︎ ↩︎
Berson A, Puri A, Ravid D, et al. Lipid interactions of amyloidogenic proteins in neurodegeneration. Nat Rev Neurosci. 2022. ↩︎